NCT04920890

Radiofrequency Intervention in Neurological Pathologies Post COVID-19

Completed NA Last updated 15 June 2025

What this trial tests

NA trial testing Radiofrequency therapy with manual therapy in Covid19 in 10 participants. Completed in 20 July 2022.

Timeline

16 June 2021

Primary endpoint
21 June 2022

20 July 2022

Quick facts

Lead sponsor	Clinica Gema Leon
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	16 June 2021
Primary completion	21 June 2022
Estimated completion	20 July 2022
Sites	1 location across Spain

Drugs / interventions tested

• Radiofrequency therapy with manual therapy

Conditions studied

• Covid19 — all drugs for Covid19 →
• Neurological Injury — all drugs for Neurological Injury →
• Olfactory Disorder — all drugs for Olfactory Disorder →
• Gustatory Agnosia — all drugs for Gustatory Agnosia →

Sponsor

Clinica Gema Leon

Who can join

Eligibility, any sex, with Covid19 or Neurological Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The sequelae that occur in post-COVID-19 patients are multiple and, at a therapeutic level, these represent a new challenge within the general context of the pandemic that the world is suffering.

The virus has managed to end thousands of lives today and many other cases are being charged as directly responsible for a multiplicity of multi-system damages that need to be diagnosed and treated. Among the most relevant, are those that can affect to neurological levels in patients without previous pahologies, and in patients at risk who already had a pathology prior to infection.

On the other hand, signs and symptoms have been observed characteristic in the organ systems described above in post-contagion patients, directly associated with sequelae SARV-CoV2. The radio frequency (RF) of electromagnetic waves represents a technology of proven efficacy and safety in multiple fields of both human and veterinary medicine. These include neurological pathologies, and very especially those that affect the locomotor system. In therapeutics there are different RF modalities depending on the modality, polarity, type of signal and frequency, which in turn translate into different therapeutic profiles, clinical indications, efficacy and safety.

Among the RF technologies most used today and that have a greater scientific background, is the one known as Resistive Capacitive Monopolar Radio Frequency at 448 kHz (INDIBA®) (RFMCR). This study aims to assess the efficacy and safety of RFMCR in the treatment of neurological sequelae in patients presenting this type of pathologies that appear after contagion by COVID-19. Through this non-invasive technique, the investigators want to show that RF can help the physical rehabilitation of these patients through metabolic stimulation, increased vascularization and oxygenation of directly affected tissues, effects of deep hyperthermia generated by the interaction of the current with the treated biological substrate, as well as the activation of tissue regeneration, the result of subthermal action. It is thus intended to improve signs such as lung capacity, dyspnea, neuropathies and global muscle capacity, which are essential for the recovery of the post-COVID-19 patients.

The hypothesis of this study is that current post-COVID-19 treatments can be significantly improved in order to prevent complications and ensure the patients' well-being.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.